From Barchart:

Healthcare giants LLY and NVO have outperformed the broader market for the past 20 years. As competition intensifies in the obesity drug sector, investors are looking for the better buy between the two.



Read more: Novo Nordisk vs. Eli Lilly: Which Mega-Cap Healthcare Stock is a Better Buy for 2024?